- Home
- BRKH vs CRVS Comparison
BRKH vs CRVS Comparison
Compare BRKH & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKH
- CRVS
- Stock Information
- Founded
- BRKH 2021
- CRVS 2014
- Country
- BRKH United States
- CRVS United States
- Employees
- BRKH N/A
- CRVS N/A
- Industry
- BRKH Blank Checks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BRKH Finance
- CRVS Health Care
- Exchange
- BRKH Nasdaq
- CRVS Nasdaq
- Market Cap
- BRKH 170.6M
- CRVS 161.4M
- IPO Year
- BRKH 2021
- CRVS 2016
- Fundamental
- Price
- BRKH $11.25
- CRVS $5.48
- Analyst Decision
- BRKH
- CRVS Buy
- Analyst Count
- BRKH 0
- CRVS 4
- Target Price
- BRKH N/A
- CRVS $10.83
- AVG Volume (30 Days)
- BRKH 31.6K
- CRVS 460.2K
- Earning Date
- BRKH 01-01-0001
- CRVS 11-05-2024
- Dividend Yield
- BRKH N/A
- CRVS N/A
- EPS Growth
- BRKH N/A
- CRVS N/A
- EPS
- BRKH N/A
- CRVS N/A
- Revenue
- BRKH N/A
- CRVS N/A
- Revenue This Year
- BRKH N/A
- CRVS N/A
- Revenue Next Year
- BRKH N/A
- CRVS N/A
- P/E Ratio
- BRKH N/A
- CRVS N/A
- Revenue Growth
- BRKH N/A
- CRVS N/A
- 52 Week Low
- BRKH $10.48
- CRVS $1.05
- 52 Week High
- BRKH $11.28
- CRVS $6.15
- Technical
- Relative Strength Index (RSI)
- BRKH 59.44
- CRVS 71.40
- Support Level
- BRKH $11.12
- CRVS $3.90
- Resistance Level
- BRKH $11.24
- CRVS $4.75
- Average True Range (ATR)
- BRKH 0.01
- CRVS 0.45
- MACD
- BRKH -0.00
- CRVS 0.09
- Stochastic Oscillator
- BRKH 48.39
- CRVS 70.22
About BRKH BurTech Acquisition Corp.
BurTech Acquisition Corp is a blank check company.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).